Results 81 to 90 of about 106,022 (294)

Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes

Journal of Diabetes Investigation
Aims To evaluate characteristics and glycemic outcomes in individuals with type 2 diabetes using injectable therapies in real‐world clinical practice in Tianjin, China.
Qiumei Zhang, Yaqing Fan, Xixi Liu, Minlu Zhang, Jiewen Zhang, Qin Du, Lei Kang, Liming Chen   +7 more
doaj   +1 more source

Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease

Journal of Biomedical Sciences
Neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) are common complications of diabetes, arising from insulin resistance, inflammation, and other pathological processes in the central nervous system. The potential
Chien-Tai Hong, Jia-Hung Chen, Chaur-Jong Hu   +2 more
semanticscholar   +1 more source

GLP‐1 Receptor Agonism Exacerbates Activity‐Based Anorexia in Mice

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists reduce food intake and body weight, suggesting they should be avoided in anorexia nervosa. However, preclinical evidence that these drugs reduce activity and reward‐seeking behavior raises the possibility that they might attenuate the compulsive‐like hyperactivity central to ABA ...
Amit Thakar, Travis E. Brown, Shane T. Hentges   +2 more
wiley   +1 more source

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Nature Communications
Glucagon-like peptide-1 receptor agonists act via appetite suppression and caloric restriction. These treatments can result in significant muscle loss, likely due to evolutionary mechanisms protecting against food scarcity as muscle is a major energy ...
Jason W. Mastaitis, Daniel Gomez, José G. Raya, Diana Li, Soo Min, Michael Stec, Sandra Kleiner, Toya McWilliams, Judith Y. Altarejos, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman   +11 more
doaj   +1 more source

Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection

Frontiers in Medicine
Endothelial dysfunction represents the critical pathophysiological mediator linking the modern epidemics of obesity, type 2 diabetes mellitus, and cardiovascular disease.
Allegra Battistoni, Linda Piras, Nicola Tartaglia, Francesco Maria Carrano, Claudia De Vitis, Emanuele Barbato   +5 more
doaj   +1 more source

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes

Alimentary Pharmacology and Therapeutics
We examined the effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) initiation on long‐term Adverse Liver Outcomes (ALO) in patients with Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) cirrhosis and type 2 diabetes using ...
Mohamed I. Elsaid, Na Li, Stephen A. Firkins, Vinod K. Rustgi, E. Paskett, C. Acharya, K. R. Reddy, Chien Wei Chiang, Khalid Mumtaz   +8 more
semanticscholar   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis

JAMA Ophthalmology
ImportanceEmerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for glycemic control in diabetes, may possess anti-inflammatory properties. Understanding their potential protective role against uveitis could provide insights into novel therapeutic strategies.ObjectiveTo evaluate whether being prescribed a ...
Mohan, Nitesh, Srivastava, Sunil K., Schulgit, Matthew J., Nowacki, Amy S., Kaelber, David C., Sharma, Sumit   +5 more
openaire   +2 more sources

Exploring Perspectives on Ozempic: A Netnographic Qualitative Evaluation of the Pro‐Eating Disorder Community on X (Formerly Twitter)

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Eating disorders (EDs) are complex conditions with medical and psychosocial implications. Social media (SM) exposure has been associated with increased body image concerns and maladaptive eating behaviors. Pro‐eating disorder (pro‐ED) communities exist across SM platforms and often perpetuate ED‐related identities and behaviors.
Daisy Sun, Tovah Yanover, Helena Katona, Jennifer Couturier   +3 more
wiley   +1 more source

Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists

Endocrinology Research and Practice, 2022
Glucagon-like peptide-1 is the most potent incretin secreted from the intestinal tract. It is synthesized by L-cells in the jejunum and distal ileum of the gastrointestinal system.
Dilek Tüzün
doaj  

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update [PDF]

Endocrinology and Metabolism
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic ...
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen   +2 more
doaj   +1 more source